Literature DB >> 18976289

Nox-2 is a modulator of fibrogenesis in kidney allografts.

A Djamali1, A Vidyasagar, M Adulla, D Hullett, S Reese.   

Abstract

We studied the role of classical phagocytic NADPH oxidase (Nox) in the pathogenesis of kidney allograft tubulointerstitial fibrosis. Immunofluorescence studies showed that Nox-2 and p22phox (electron transfer subunits of Nox) colocalized in the tubulointerstitium of human kidney allografts. Tubular Nox-2 also colocalized with alpha-SMA in areas of injury, suggestive of epithelial-to-mesenchymal transition (EMT). Interstitial macrophages (CD68(+)) and myofibroblasts (alpha-SMA(+)) expressed Nox-2 while graft infiltrating T cells (CD3(+)) and mature fibroblasts (S100A4(+)) were Nox-2(-). These results were confirmed in the Fisher-to-Lewis rat kidney transplant model. Areas of tubulitis were associated with Nox-2 and alpha-SMA, suggestive of EMT. Immunoblot analyses showed that Nox-2 upregulation was associated with oxidative stress (nitrotyrosine) and fibrogenesis (alpha-SMA and phospho-Smad2) at 3 weeks and 6 months. Allografts treated with Nox inhibitors (DPI or apocynin) for 1 week showed reduced fibronectin and phospho-Smad2 and increased E-cadherin levels. Cyclosporine A, TGF-beta1 and angiotensin II increased Nox-2 mRNA levels 2- to 7-fold in vitro (NRK52E cells). Treatment with specific Nox inhibitors (DPI or apocynin) prevented the downregulation of E-cadherin and upregulation of fibronectin transcripts. In aggregate, these studies suggest that Nox-2 is involved in the pathogenesis of allograft tubulointerstitial fibrosis via activation transcription factor Smad2, EMT and myofibroblasts.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976289      PMCID: PMC3572864          DOI: 10.1111/j.1600-6143.2008.02463.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  32 in total

1.  Chronic allograft nephropathy.

Authors:  Robert B Colvin
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

2.  Death after graft loss: an important late study endpoint in kidney transplantation.

Authors:  Bruce Kaplan; Herwig-Ulf Meier-Kriesche
Journal:  Am J Transplant       Date:  2002-11       Impact factor: 8.086

3.  Chronic administration of the oral hypoglycaemic agent diphenyleneiodonium to rats. An animal model of impaired oxidative phosphorylation (mitochondrial myopathy).

Authors:  J M Cooper; R K Petty; D J Hayes; J A Morgan-Hughes; J B Clark
Journal:  Biochem Pharmacol       Date:  1988-02-15       Impact factor: 5.858

4.  Long-term dietary L-arginine supplementation attenuates proteinuria and focal glomerulosclerosis in experimental chronic renal transplant failure.

Authors:  Ester W J A Albrecht; Harry van Goor; Annemieke Smit-van Oosten; Coen A Stegeman
Journal:  Nitric Oxide       Date:  2003-02       Impact factor: 4.427

Review 5.  NAD(P)H oxidase: role in cardiovascular biology and disease.

Authors:  K K Griendling; D Sorescu; M Ushio-Fukai
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

6.  Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation.

Authors:  Herwig-Ulf Meier-Kriesche; Rajendra Baliga; Bruce Kaplan
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

7.  The natural history of chronic allograft nephropathy.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

8.  Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: reversal by lifelong antioxidant supplementation.

Authors:  Chang-De Zhan; Ram K Sindhu; Nosratola D Vaziri
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

9.  Oxidative stress in chronic renal allograft nephropathy in rats: effects of long-term treatment with carvedilol, BM 91.0228, or alpha-tocopherol.

Authors:  Uwe Göttmann; Jens Oltersdorf; Meike Schaub; Thomas Knoll; Walter E Back; Fokko J van der Woude; Claude Braun
Journal:  J Cardiovasc Pharmacol       Date:  2003-09       Impact factor: 3.105

Review 10.  Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis.

Authors:  Surmeet Bedi; Aparna Vidyasagar; Arjang Djamali
Journal:  Transplant Rev (Orlando)       Date:  2008-01       Impact factor: 3.943

View more
  39 in total

Review 1.  The myofibroblast, a key cell in normal and pathological tissue repair.

Authors:  Ian A Darby; Noraina Zakuan; Fabrice Billet; Alexis Desmoulière
Journal:  Cell Mol Life Sci       Date:  2015-12-17       Impact factor: 9.261

Review 2.  Contribution of epithelial plasticity to renal transplantation-associated fibrosis.

Authors:  A Hertig; S N Flier; R Kalluri
Journal:  Transplant Proc       Date:  2010-11       Impact factor: 1.066

3.  Microcystin exposure worsens nonalcoholic fatty liver disease associated ectopic glomerular toxicity via NOX-2-MIR21 axis.

Authors:  Sutapa Sarkar; Firas Alhasson; Diana Kimono; Muayad Albadrani; Ratanesh K Seth; Shuo Xiao; Dwayne E Porter; Geoff I Scott; Bryan Brooks; Mitzi Nagarkatti; Prakash Nagarkatti; Saurabh Chatterjee
Journal:  Environ Toxicol Pharmacol       Date:  2019-10-20       Impact factor: 4.860

4.  Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer.

Authors:  Peng Wang; Qiao Shi; Wen-Hong Deng; Jia Yu; Teng Zuo; Fang-Chao Mei; Wei-Xing Wang
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

5.  Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent.

Authors:  Tomonori Aoyama; Yong-Han Paik; Sumio Watanabe; Benoît Laleu; Francesca Gaggini; Laetitia Fioraso-Cartier; Sophie Molango; Freddy Heitz; Cédric Merlot; Cédric Szyndralewiez; Patrick Page; David A Brenner
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

6.  Complete B Cell Deficiency Reduces Allograft Inflammation and Intragraft Macrophages in a Rat Kidney Transplant Model.

Authors:  Sarah E Panzer; Nancy A Wilson; Bret M Verhoven; Ding Xiang; C Dustin Rubinstein; Robert R Redfield; Weixiong Zhong; Shannon R Reese
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

Review 7.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

8.  Nox2 and Cyclosporine-Induced Renal Hypoxia.

Authors:  Arjang Djamali; Nancy A Wilson; Elizabeth A Sadowski; Wei Zha; David Niles; Omeed Hafez; Justin R Dorn; Thomas R Mehner; Paul C Grimm; F Michael Hoffmann; Weixiong Zhong; Sean B Fain; Shannon R Reese
Journal:  Transplantation       Date:  2016-06       Impact factor: 4.939

Review 9.  Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

Authors:  Arjang Djamali; Millie Samaniego
Journal:  Transplantation       Date:  2009-11-27       Impact factor: 4.939

10.  The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model.

Authors:  Shannon Reese; Aparna Vidyasagar; Lynn Jacobson; Zeki Acun; Stephane Esnault; Debra Hullett; James S Malter; Arjang Djamali
Journal:  Fibrogenesis Tissue Repair       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.